The Cure Starts Now follows an extensive grant approval process to ensure your dollars make the biggest impact to homerun cancer research. Take comfort in knowing that The Cure Starts Now only funds: research that follows our mission, research that is non-duplicative, and research that is financially sound.


The Cure Starts Now has funded $23,514,997 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 149 grants at over 100 hospitals in 17 countries.




Funding of PBTCF 2021: PBTC-059 - $25,000

Amount
$25,000.00
Date
January 2021

Phase 1 Trial of Autologous HER2-specific CAR T cells in Pediatric Patients with Refractory or Recurrent Ependymoma

International DIPG/DMG Registry And Repository - $1,508,198

Amount
$1,508,198.00
Date
December 2020

Children's Cancer Institute - $99,251

Amount
$99,251.00
Date
September 2020

Discovering New Epigenetic Players in DIPG Oncogenesis

Northwestern Memorial Hospital - $110,000

Amount
$110,000.00
Date
September 2020

Development of Histone Demethylase Inhibitor Against DIPG

The Hospital for Sick Children - $100,000

Amount
$100,000.00
Date
September 2020

Methionne Deptrivation as a Therapeutic Strategy for Diffuse Intrinsic Pontine Glioma

Hunter Medical Research Institute - $145,640

Amount
$145,640.00
Date
September 2020

Combatt DMG: Combined Anti-tumor Targeting of Diffuse Midline Gliomas

CONNECT Consortium - $489,801.26

Amount
$489,801.00
Date
September 2020

CONNECT (COllaborative Network for NEurooncology Clinical Trials) Consortium

International DIPG/DMG Registry And Repository - $862,671

Amount
$862,671.00
Date
May 2020

Funding of PBTCF 2020: PBTC-058 - $25,000

Amount
$25,000.00
Date
January 2020

PBTC-058: Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma

Sydney Children's Hospital - $151,468

Amount
$151,468.00
Date
December 2019

Developing New Epigenetic Combination Treatments Against DIPG.

Oncoceutics ONC201 - $100,000

Amount
$100,000.00
Date
December 2019

Expansion of the ONC201 Compassionate Use.

University of Sydney - $100,000

Amount
$100,000.00
Date
November 2019

Targeting hypoxia and mitochondrial metabolism with repurposing drugs as an approach of radiosensitization for diffuse intrinsic pontine gliomas.

University of Michigan Hospitals - $157,856

Amount
$157,856.00
Date
November 2019

Therapeutic reversal of pre-natal pontine ID1 signaling in DIPG

Dayton Children's Hospital - $69,600

Amount
$69,600.00
Date
November 2019

Responses of distinct cell populations to PDGFRA inhibitors in diffuse intrinsic pontine glioma.

Institute of Cancer Research - $121,863

Amount
$121,863.00
Date
November 2019

Targeting Top3A-Amplified DIPG cells by Sirtuin inhibition.